| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8733530 | Critical Reviews in Oncology/Hematology | 2018 | 31 Pages |
Abstract
SBRT of oligometastatic CRC offers high LC with low morbidity and toxicity. It requires more observational studies and randomized trials but available data on clinical efficacy is promising, however not yet matured.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
J. Kobiela, P. Spychalski, G. Marvaso, D. Ciardo, V. Dell'Acqua, F. Kraja, A. BÅażyÅska-Spychalska, A.J. ÅachiÅski, A. Surgo, R. Glynne-Jones, B.A. Jereczek-Fossa,